但是,ABC型DLBCL对BTK抑制剂反应的分子机制,尤其是MCD型DLBCL患者表现出的如此特殊的反应的原因仍未可知。 近日,来自美国国立卫生研究院的Louis M.Staudt团队和德国法兰克福大学的Thomas Oellerich团队在Cancer Cell上在线发表题为Response to Br...
但是,ABC型DLBCL对BTK抑制剂反应的分子机制,尤其是MCD型DLBCL患者表现出的如此特殊的反应的原因仍未可知。 近日,来自美国国立卫生研究院的Louis M.Staudt团队和德国法兰克福大学的Thomas Oellerich团队在Cancer Cell上在线发表题为Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chron...
本文描述了激酶抑制剂化合物,此类抑制剂的合成方法和在疾病的治疗中使用此类抑制剂的方法. This article describes the kinase inhibitor compounds, synthetic methods such inhibitors and methods of using such inhibitors in the treatment of disease. 本文进一步描述了用于测定包括激酶在内的蛋白质的适当抑制剂的...
is involved in the activation and function of B cells and myeloid cells, and is currently regarded as a drug target to lighten both dysregulated innate and adaptive immunity [16]. BTK inhibitors (BTKi), which could penetrate the blood-brain barrier (BBB), may act on ...
[2] Campbell R, Chong G, Hawkes E A. Novel indications for Bruton’styrosine kinase inhibitors, beyond hematological malignancies[J]. Journal ofclinical medicine, 2018, 7(4): 62. [3] Coutré S E, Furman R R, Flinn I W, et al. Extended treatment withsingle-agent ibrutinib at the 420...
Bruton’s tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon
Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclos
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are current standard of care for patients with EGFR mutation and metastatic non-small-cell lung carcinoma (NSCLC), but most patients using EGFR TKIs acquire resistance later. So, overcoming resistance of EGFR TKIs has become...
The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same. Inventors: Bui, Minna (Oakland, CA, US) Conlon, Patrick (Wakefield, MA, US) Cuervo, Julio H. (Arlington, MA, US) Erlanson, Daniel A. (San Francisco, CA, US)...
33extracellular signal-regulated kinase,34and nuclear factor κ light-chain enhancer of activated B cells pathways.35Bruton tyrosine kinase also plays an essential role in chemokine-mediated chemotaxis and adhesion of B cells.36Bruton tyrosine kinase inhibitorsthus serve as a promising therapeutic target...